The members of the supervisory board of the LTS AG have been newly elected.
On June 28th 2019, the shareholders meeting of the LTS AG has elected the four represen¬tatives of the equity owners to the supervisory board of the LTS AG.

Reelected to the supervisory board were:
Prof. Dr. Christof Hettich, lawyer, Schwetzingen
Dr. Jochen Wolf, Dipl.-Kaufmann, Weinsberg

Newly elected to the supervisory board were:
Mr. Oliver Hopp, business entrepreneur, Walldorf
Mr Rüdiger Busley, lawyer and tax advisor, Heidelberg

The employees of the LTS AG have already elected two employee representatives to the supervisory board:
Mrs. Erika Weiler, chairwoman of the workers council of the LTS AG
Mr. Michael Mildner, clerk salaries & administration LTS AG

The mandate of the previous members of the supervisory board, Prof. Dr. Norbert Loos, Dr. Mathias Hothum, Mr Hermann Pauken and Mr Uwe Bungarten ended with the closing of the shareholders meeting of LTS AG.

The management board of LTS congratulates the new members of the supervisory board to their election and thanks the parting members of the supervisory board for the good cooperation over many years for the benefit of LTS AG.

About LTS:
LTS Lohmann Therapy-Systeme AG is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) for the pharmaceutical industry. LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 30 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Micro Array Patches for the transdermal delivery of large molecule, biological actives. Founded in 1984, LTS operates today from two sites in Andernach, Germany and West Caldwell, NJ, USA and a representation in Shanghai, China.

Contact: Dr. Iris Schnitzler, e-mail: